Sign in
CompletedPhase 2

NAPO - Novel Approach for Oligospermia

Key facts

Who runs it
Herlev Hospital
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
60 people enrolled
Started
1 Apr 2024
Ended
27 Jan 2025
Type of study
Interventional
Record updated
19 December 2023

Who can take part

Age
18 years to 64 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Infertile men >18 years and <60 years of age with reduced sperm production (Sperm concentration <2 mio/mL) - Serum AMH > 30 pmol/L

Who cannot take part

  • Poor dental status og dental implants
  • Men with chronic diseases (diabetes mellitus, thyroid disease, endocrine diseases requirering treatment such as sarcoidosis, tuberculosis, wegeners, vasculitis as well as inflammatory bowel diseases e.g. chron's disease or ulcerative colitis etc)
  • Latex allergy
  • Men with active or previous malignant disease
  • Serum FSH <3 IU/L
  • Serum ionized calcium < 1,18 mmol/L, Total calcium < 2.14 mmol/L or Albumin corrected calcium <2.17 mmol/L
  • Serum 25OHD < 25 nmol/L
  • eGFR <60 mL/min/1.73m^2
  • Any case with indication for testis biopsy
  • BMI >35 kg/m^2
  • Sperm cell concentration <0.01 mio/mL
  • Men in treatment for osteoporosis
  • Men with obstructive oligospermia (Sperm volume <0.9 mL) or who has been vasectomized

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this intervention is to investigate whether Denosumab can improve semen quality in a subgroup of infertile men.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
19 December 2023